Researchers report on the first safety and efficacy of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for patients with relapsed/refractory Mantle cell lymphoma. This study was presented at...
The OASIS trial evaluates the efficacy of ibrutinib, venetoclax, and obinutuzumab in newly diagnosed mantle cell lymphoma, reporting a 5-year progression-free survival (PFS) rate of 80% and overall survival...
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
A retrospective study highlights the safety and feasibility of outpatient administration of brexucabtagene autoleucel for patients with acute lymphoblastic leukemia and mantle cell lymphoma, showing...
Researchers assessed the efficacy of venetoclax-based treatments for patients with relapsed/refractory chronic lymphocytic leukemia. This study was presented at the 65th ASH Annual Meeting & Exposition...
In effort to understand the effect of the COVID-19 pandemic among patients with sickle cell disease, researchers compared outcomes and characteristics of hospitalized patients both before and during the...
In their case-controlled study that utilized the National Inpatient Sample 2016-2019 database, researchers set out to examine the relationship between leukemia and sickle cell trait.
The researchers analyzed 569 patients with multiple myeloma, stratified patients on the basis of their percentage of CD56-expressing clonal MM cells, and then evaluated patient outcomes based on this...
To examine the prognostic value of flow cytometry plus PET/CT scanning for detecting minimal residual disease in patients with multiple myeloma, researchers conducted an observational cohort study of 94...
For their study, the researchers aimed to clarify the mechanisms behind racial and ethnic disparities in multiple myeloma disease outcomes by investigating the demographic, clinical, and molecular features...
